Supplementary Table 1

WNV Primer	Sequence (5' to 3')	Application
20F	AGTAGTTCGCCTGTGTGAGC	PCR/Seq
491R	ATTTACCGTCATCATCACCT	Seq
912R	ACACTCCTTCCAAGAAGTCTC	Seq
1493R	TTCTCCAAGCTTTAGTGTGTA	Seq
2492R	CTCAGCTCTTGGCCGGCTGAT	Seq
2993R	GTCACATTCAGTTGTGTTGC	Seq
3026F	TGACTCGAAGATCATTGGAA	PCR/ Seq
3497R	TGTGACTGCACGAGGGTCTT	PCR/ Seq
3998R	GGTGTTAGCAGGGCTAGCGA	Seq
4496R	ATCCATATCTTCCAAGGTGC	cDNA
4997R	GATGTTCCAGTGGGGAAGT	Seq
5501R	GTGGAAATGTAACCTCTTGC	Seq
5531F	CATTTCCACAAAGGTCGAGC	PCR/ Seq
6002R	CCAACTTGCGACGGATTTCT	PCR/ Seq
6503R	CCCATGAAGTGCTCAGGCAT	cDNA/Seq
7004R	AAGTCCAAAAGAAACTCTCC	Seq
7505R	GTGATCAAAATTCCGGCTTC	Seq
7535F	TTTGATCACGGCCGCAGCGG	Seq
8006R	AGTTGGGGCTCTTCATGTCC	Seq
8036F	GCCCCAACTAGTGCAAAGTT	Seq
8537F	CAAGAACAGGATTGAACGAC	PCR/ Seq
9008R	GACATTCCCCCCGCAGATGT	PCR
9038F	GGGGGGAATGTCACACTTGC	Seq

9509R	TGAAAGTGTTTAGGGCGTAG	Seq
9539F	ACACTTTCACCAACCTGGCC	Seq
10040F	TGGCCAACGCCATTTGCTCC	Seq
10541F	TTCCCGCCACCGGAAGTTGA	Seq
10511R	TGGCGGGAACTTCCCGGCCT	cDNA
11012R	AGATCCTGTGTTCTCGCACC	cDNA/PCR

WNV RNA was harvested from viral supernatants and converted to four overlapping cDNA (~ 3 to 4 kb in size) by reverse transcription (Superscript III, Invitrogen) using the following primers: 11012R, 10511R, 6503R, and 4496R (marked cDNA). Subsequently, PCR was performed with overlapping paired primers (20F/3497R, 3026F/6002R, 5531F/9008R, and 8537F/11012R; marked PCR) using a Hi-Fidelity Taq Polymerase (Invitrogen). Products were sequenced bi-directionally with sequencing primers (marked Seq).